Clinical data | |
---|---|
Trade names | Voxzogo |
Other names | BMN-111 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C176H290N56O51S3 |
Molar mass | 4102.78 g·mol−1 |
3D model (JSmol) |
|
SMILES
| |
InChI
|
Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia.[3][4][5]
The most common side effects include injection site reactions (such as swelling, redness, itching, or pain), vomiting, and decreased blood pressure.[3][4][5]
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth.[4] The average height of an adult with achondroplasia is approximately four feet.[4] People with achondroplasia have a genetic mutation that causes a certain growth regulation gene called fibroblast growth factor receptor 3 to be overly active, which prevents normal bone growth.[4] Vosoritide works by binding to a specific receptor called natriuretic peptide receptor-B that reduces the growth regulation gene's activity and stimulates bone growth.[4]
Vosoritide was approved for medical use in the European Union in August 2021,[5][6][7] and in the United States in November 2021.[4][8] The US Food and Drug Administration considers it to be a first-in-class medication.[9]
Voxzogo EPAR
was invoked but never defined (see the help page).